Allergen immunotherapy (AIT), which has an established position in the management of allergic rhinitis with systemic IgE-sensitization features, has not been evaluated in LAR patients to the extent that its inclusion as a recommended management option is permitted. This evidence concerns the gene IGHE and allergic rhinitis.